| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Cambium Oncology |
| Recipient: You |
| Company: Taobob LLC |
| Recipient: You |
| Company: GenCart |
| Recipient: You |
| Company: Coherus Biosciences |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Novartis |
| Recipient: You |
| Company: Celgene |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: G1 Therapeutics |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: MedImmune |
| Recipient: You |
| Company: BerGenBio |
| Recipient: You |
| Company: Lilly |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: PharmaMar |
| Recipient: You |
| Company: Boehringer Ingelheim |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Xcovery |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Jazz Pharmaceuticals |
| Recipient: You |
| Company: Zentalis |
| Recipient: You |
| Company: Wells Fargo |
| Recipient: You |
| Company: Ipsen |
| Recipient: You |
| Company: Eisai |
| Recipient: You |
| Company: Roche/Genentech |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
| Company: Exelixis |
| Recipient: You |
| Company: BeiGene |
| Recipient: You |
| Company: Triptych Health Partners |
| Recipient: You |
| Company: Daichi |
| Recipient: You |
| Company: Xcovery |
| Recipient: You |
| Company: Coherus Biosciences |
| Recipient: You |
|
| Speakers' Bureau |
| Company: Abbvie |
| Recipient: You |
|
| Research Funding |
| Company: Corvus Pharmaceuticals |
| Recipient: You |
| Company: Novartis |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: Bayer |
| Recipient: Your Institution |
| Company: Regeneron |
| Recipient: Your Institution |
| Company: AstraZeneca/MedImmune |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: G1 Therapeutics |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: United Therapeutics |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Loxo/Lilly |
| Recipient: Your Institution |
| Company: Fujifilm |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Aeglea Biotherapeutics |
| Recipient: Your Institution |
| Company: Incyte |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Oncorus |
| Recipient: Your Institution |
| Company: Ipsen |
| Recipient: Your Institution |
| Company: GlaxoSmithKline |
| Recipient: Your Institution |
| Company: Calithera Biosciences |
| Recipient: Your Institution |
| Company: Eisai |
| Recipient: Your Institution |
| Company: WindMIL |
| Recipient: Your Institution |
| Company: Turning Point Therapeutics |
| Recipient: Your Institution |
| Company: Roche/Genentech |
| Recipient: Your Institution |
| Company: Mersana |
| Recipient: Your Institution |
| Company: Meryx |
| Recipient: Your Institution |
| Company: Boehringer Ingelheim |
| Recipient: Your Institution |
| Company: Boehringer Ingelheim |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS
THROUGH SUPPRESSION OF STAT3 |
| Recipient: Your Institution |
| Please describe: SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS
RELATED THERETO |
| Recipient: Your Institution |
| Please describe: DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor)
|
| Recipient: Your Institution |
| Please describe: Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) |
| Recipient: Your Institution |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| Company: Roche/Genentech |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
|
| (OPTIONAL) Uncompensated Relationships |
| Company: Reflexion Medical |
| Recipient: You |
|
| (OPTIONAL) Open Payments Link |
|
| Open Payments URL: https://openpaymentsdata.cms.gov/physician/253457 |
|